Objectives: The American Society of Hematology (ASH) invites you to New Orleans, LA, for its 55th annual meeting. As the premier hematology event of the year, this meeting is an invaluable educational experience for all attendees and provides:
Opportunities to grow professionally by learning about the latest clinical updates in research, therapies, and practice strategies through Education and Scientific Programs
Networking events that will allow you to connect with more than 20,000 colleagues from around the globe to learn and share your ideas
A chance to review thousands of select scientific abstracts that are presented each year
Who Should Attend: Hematologists, Hematologist-Oncologists, Hemapathologists, Oncologists, Allied Health Professionals
Sep 23, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.